Diabetes, insulin, and development of acute lung injury

Critical Care Medicine

Volumn 37, Issue 8, 2009, Pages 2455-2464

  Honiden, Shyoko ^a   Gong, Michelle N ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Diabetes mellitus; Hyperglycemia; Insulin

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; DIABETES MELLITUS; HUMAN; HYPERGLYCEMIA; IMMUNOPATHOGENESIS; INSULIN METABOLISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 68249106529     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181a0fea5     Document Type: Review

References (123)

1. Bernard GR, Artigas A, Brigham KL, et al; The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818-824
2. Chabot F, Mitchell JA, Gutteridge JMC, et al: Reactive oxygen species in acute lung injury. Eur Respir J 1998; 11:745-757
3. Suratt BT, Parsons PE: Mechanisms of acute lung injury/acute respiratory distress syndrome. Clin Chest Med 2006; 27: 579-589
4. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 2000; 342:1334-1349
5. Rubenfeld GD, Caldwell E, Peabody E, et al: Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353:1685-1693
6. Hudson LD, Milberg JA, Anardi D, et al: Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 151:293-301
7. Van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359-1367
8. Van den Berghe G, Wilmer A, Hermans G, et al: Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449-461
9. Brunkhorst FM, Engel C, Bloos F, et al; German Competence Network Sepsis (Sep-Net). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125-139
10. Grey NJ, Perdrizet GA: Reduction of nosocomial infections in the surgical intensivecare unit by strict glycemic control. Endocr Pract 2004; 10(suppl 2):46-52
11. Krinsley JS: Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 2004; 79:992-1000
12. Sykes E, Cosgrove JF: Acute renal failure and the critically ill surgical patient. Ann R Coll Surg Engl 2007; 89:22-29
13. Ahmad R, Cherry RA, Lendel I, et al: Increased hospital morbidity among trauma patients with diabetes mellitus compared with age- and injury severity score-matched control subjects. Arch Surg 2007; 142: 613-618
14. Moss M, Guidot DM, Steinberg KP, et al: Diabetic patients have a decreased incidence of acute respiratory distress syndrome. Crit Care Med 2000; 28:2187-2192
15. Frank JA, Nuckton TJ, Matthay MA: Diabetes mellitus: a negative predictor for the development of acute respiratory distress syndrome from septic shock. Crit Care Med 2000; 28:2645-2646
16. Gong MN, Thompson BT, Williams P, et al: Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med 2005; 33:1191-1198
17. Iscimen R, Cartin-Ceba R, Yilmaz M, et al: Risk factors for the development of acute lung injury in patients with septic shock: an observational cohort study. Crit Care Med 2008; 36:1518-1522
18. Boichot E, Sannomiya P, Escofier N, et al: Endotoxin-induced acute lung injury in rats. Role of insulin. Pulm Pharmacol Ther 1999; 12:285-290
19. Alba-Loureiro TC, Martins EF, Landgraf RG, et al: Role of insulin on PGE2 generation during LPS-induced lung inflammation in rats. Life Sci 2006; 78:578-585
20. De Oliveira Martins J, Meyer-Pflug AR, Alba-Loureiro TC, et al: Modulation of lipopolysaccharide-induced acute lung inflammation: role of insulin. Shock 2006; 25: 260-266
21. Wright JK, Nwariaku FN, Clark J, et al: Effect of diabetes mellitus on endotoxininduced lung injury. Arch Surg 1999; 134: 1354-1359
22. Bellmeyer A, Martino JM, Chandel NS, et al: Leptin resistance protects mice from hyperoxia-induced acute lung injury. Am J Respir Crit Care Med 2007; 175:587-594
23. Barazzone-Argiroffo C, Muzzin P, Donati YR, et al: Hyperoxia increases leptin production: a mechanism mediated through endogenous elevation of corticosterone. Am J Physiol Lung Cell Mol Physiol 2001; 281:L1150-L1156
24. Yilmaz M, Keegan MT, Iscimen R, et al: Toward the prevention of acute lung injury: protocol-guided limitation of large tidal volume ventilation and inappropriate transfusion. Crit Care Med 2007; 35:1660-1666
25. Bajwa EK, Gong MN, Thompson BT, et al: Diabetes, but not hyperglycemia, is protective against ARDS. Paper presented at: ATS 2006 International Conference A831, San Diego, CA, May 19-24, 2006
26. Wasmuth HE, Kunz D, Graf J, et al: Hyperglycemia at admission to the intensive care unit is associated with elevated serum concentrations of interleukin-6 and reduced ex vivo secretion of tumor necrosis factoralpha. Crit Care Med 2004; 32:1109-1114
27. Leonidou L, Mouzaki A, Michalaki M, et al: Cytokine production and hospital mortality in patients with sepsis-induced stress hyperglycemia. J Infect 2007; 55:340-346
28. Chang LY, Lin TY, Hsu KH, et al: Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 1999; 354: 1682-1686
29. Chang LY, Lin TY, Huang YC, et al: Comparison of enterovirus 71 and coxsackievirus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 1999; 18:1092-1096
30. Chen HI, Kao SJ, Wang D, et al: Acute respiratory distress syndrome. J Biomed Sci 2003; 10:588-592
31. Vanhorebeek I, De Vos R, Mesotten D, et al: Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet 2005; 365:53-59
32. Funari AP, Zerr KJ, Grunkemeier GL, et al: Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67:352-360
33. Perner A, Nielsen SE, Rask-Madsen J: High glucose impairs superoxide production from isolated blood neutrophils. Intensive Care Med 2003; 29:642-645
34. Nielson CP, Hindson DA: Inhibition of polymorphonuclear leukocyte respiratory burst by elevated glucose concentrations in vitro. Diabetes 1989; 38:1031-1035
35. Rassias AJ, Marrin CA, Arruda J, et al: Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. Anesth Analg 1999; 88:1011-1016
36. Ling PR, Smith RJ, Bistrian BR: Hyperglycemia enhances the cytokine production and oxidative responses to a low but not high dose of endotoxin in rats. Crit Care Med 2005; 33:1084-1089
37. Iwasaki Y, Kambayashi M, Asai M, et al: High glucose alone, as well as in combination with proinflammatory cytokines, stimulates nuclear factor kappa-B-mediated transcription in hepatocytes in vitro. J Diabetes Complications 2007; 21:56-62
38. Sagone AL, Greenwald J, Kraut EH, et al: Glucose: a role as a free radical scavenger in biological systems. J Lab Clin Med 1983; 101:97-104
39. Choi SW, Benzie IF, Ma SW, et al: Acute hyperglycemia and oxidative stress: direct cause and effect? Free Radic Biol Med 2008; 44:1217-1231
40. Bayraktutan U, Weidig P, McMaster D, et al: High glucose mediates prooxidant and antioxidant enzyme activities in coronary endothelial cells. Diabetes Obes Metab 2004; 6:432-441
41. West IC: Radicals and oxidative stress in diabetes. Diabet Med 2000; 17:171-180
42. Hagiwara S, Iwasaka H, Hasegawa A, et al: Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit Care Med 2008; 36:2407-2413
43. Ramasamy R, Yan SF, Herold K, et al: Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann N Y Acad Sci 2008; 1126:7-13
44. He M, Kubo H, Ishizawa K, et al: The role of the receptor for advanced glycation endproducts in lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2007; 293: L1427-L1436
45. Zhang H, Tasaka S, Shiraishi Y, et al: Role of soluble receptor for advanced glycation end-products on endotoxin-induced lung injury. Am J Respir Crit Care Med 2008; 178:356-362
46. Liliensiek B, Weigand MA, Bierhaus A, et al: Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113:1641-1650
47. Uchida T, Shirasawa M, Ware LB, et al: Receptor for advanced glycation endproducts is a marker of type 1 cell injury in acute lung injury. Am J Respir Crit Care Med 2006; 173:1008-1015
48. Calfee CS, Ware LB, Eisner MD, et al; the NHLBI ARDS Network. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 2008; 63:1083-1089
49. Yan SF, Ramasamy R, Schmidt AM: Mechanisms of disease: advanced glycation endproducts and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008; 4:285-293
50. Clynes R, Moser B, Yan SF, et al: Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med 2007; 7:743-751
51. Donato R: RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr Mol Med 2007; 7:711-724
52. Morbini P, Villa C, Campo I, et al: The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol 2006; 19:1437-1445
53. Vamecq J, Latruffe N: Medical significance of peroxisome proliferator-activated receptors. Lancet 1999; 354:141-148
54. Corton JC, Anderson SP, Stauber A: Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 2000; 40:491-518
55. Tö njes A, Stumvoll M: The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma in diabetes risk. Curr Opin Clin Nutr Metab Care 2007; 10:410-414
56. Ghoussaini M, Meyre D, Lobbens S, et al: Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Med Genet 2005; 6:11
57. Doney AS, Fischer B, Cecil JE, et al: Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia 2004; 47:555-558
58. Deeb SS, Fajas L, Nemoto M, et al: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20:284-287
59. Becker J, Delayre-Orthez C, Frossard N, et al: Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol 2006; 20:429-447
60. Catalano M, Cortelazzo A, Santi R, et al: The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (receptor for advanced glycation endproducts) and the presence of peripheral arterial disease. Clin Biochem 2008; 41: 981-985
61. Cuzzocrea S: Peroxisome proliferator-activated receptors and acute lung injury. Curr Opin Pharmacol 2006; 6:263-270
62. Standiford TJ, Keshamouni VG, Reddy RC: Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair. Proc Am Thorac Soc 2005; 2:226-231
63. Rehan VK, Wang Y, Patel S, et al: Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents hyperoxia-induced neonatal rat lung injury in vivo. Pediatr Pulmonol 2006; 41:558-569
64. Liu D, Zeng BX, Zhang SH, et al: Rosiglitazone, an agonist of peroxisome proliferatoractivated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia. Inflamm Res 2005; 54: 464-470
65. Cuzzocrea S, Mazzon E, Di Paola R, et al: The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. J Leukoc Biol 2006; 79:999-1010
66. Genovese T, Mazzon E, Di Paola R, et al: Role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha in the development of bleomycin-induced lung injury. Shock 2005; 24: 547-555
67. Ware LB, Matthay MA: Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol Lung Cell Mol Physiol 2002; 282:L924-L940
68. LeRoith D, Yakar S: Mechanisms of disease: metabolic effects of growth hormone and insulin like growth factor 1. Nat Clin Pract Endocrinol Metab 2007; 3:302-310
69. Acerini CL, Harris DA, Matkyka KA, et al: Effects of low dose recombinant human insulin-like growth factor 1 on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin- dependent diabetes mellitus. Metabolism 1998; 47: 1481-1489
70. Moses AC, Young SC, Morrow LA, et al: Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996; 45:91-100
71. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, et al: Insulin-like growth factor I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 1992; 90: 2234-2241
72. Mohamed-Ali V, Pinkney J: Therapeutic potential of insulin-like growth factor-1 in patients with diabetes mellitus. Treat Endocrinol 2002; 1:399-410
73. Schnapp LM, Donohoe S, Chen J, et al: Mining the acute respiratory distress syndrome proteome: identification of the insulin-like growth factor (IGF)/IGF-binding protein-3 pathway in acute lung injury. Am J Pathol 2006; 169:86-95
74. Chetty A, Nielsen HC: Regulation of cell proliferation by insulin-like growth factor 1 in hyperoxia-exposed neonatal rat lung. Mol Genet Metab 2002; 75:265-275
75. Krein PM, Sabatini PJ, Tinmouth W, et al: Localization of insulin-like growth factor-I in lung tissues of patients with fibroproliferative acute respiratory distress syndrome. Am J Respir Crit Care Med 2003; 167:83-90
76. Ahamed K, Epaud R, Holzenberger M, et al: Deficiency in type 1 insulin-like growth factor receptor in mice protects against oxygen-induced lung injury. Respir Res 2005; 6:31
77. Narasaraju TA, Chen H, Weng T, et al: Expression profile of IGF system during lung injury and recovery in rats exposed to hyperoxia: a possible role of IGF-1 in alveolar epithelial cell proliferation and differentiation. J Cell Biochem 2006; 97:984-998
78. Hansen TK, Thiel S, Wouters PJ, et al: Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003; 88:1082-1088
79. Dandona P, Aljada A, Mohanty P, et al: Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001; 86:3257-3265
80. Jeschke MG, Klein D, Herndon DN: Insulin treatment improves the systemic inflammatory reaction to severe trauma. Ann Surg 2004; 239:553-560
81. Brix-Christensen V, Andersen SK, Andersen R, et al: Acute hyperinsulinemia restrains endotoxin-induced systemic inflammatory response: an experimental study in a porcine model. Anesthesiology 2004; 100: 861-870
82. Jeschke MG, Klein D, Bolder U, et al: Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology 2004; 145:4084-4093
83. Haider DG, Schaller G, Kapiotis S, et al: The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49:1909-1914
84. Krogh-Madsen R, Møller K, Dela F, et al: Effect of hyperglycemia and hyperinsulinemia on the response of IL-6, TNF-alpha, and FFAs to low-dose endotoxemia in humans. Am J Physiol Endocrinol Metab 2004; 286:E766-E772
85. Mesotten D, Swinnen JV, Vanderhoydonc F, et al: Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab 2004; 89: 219-226
86. Nielsen JS, Larsson A, Brix-Christensen V, et al: Endotoxemia-induced lymphocyte apoptosis is augmented by a hyperinsulinemic-euglycemic clamp. Anesthesiology 2005; 102:768-773
87. Leffler M, Hrach T, Stuerzl M, et al: Insulin attenuates apoptosis and exerts antiinflammatory effects in endotoxemic human macrophages. J Surg Res 2007; 143: 398-406
88. Langouche L, Vanhorebeek I, Vlasselaers D, et al: Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 2005; 115:2277-2286
89. Landin K, Tengborn L, Chmielewska J, et al: The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost 1991; 65:130-133
90. Agus MSD, Javid PJ, Ryan DP, et al: Intravenous insulin decreases protein breakdown in infants on extracorporeal membrane oxygenation. J Pediatr Surg 2004; 39:839-844
91. Weekers F, Giulietti AP, Michalaki M, et al: Metabolic, endocrine, and immune effects of stress hyperglycemia in a rabbit model of prolonged critical illness. Endocrinology 2003; 144:5329-5338
92. Ellger B, Langouche L, Richir M, et al: Modulation of regional nitric oxide metabolism: blood glucose control or insulin ? Intensive Care Med 2008; 34:1525-1533
93. Ware LB: Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med 2006; 27:338-349
94. Donnelly M, Condron C, Murray, et al: Modulation of the glycemic response using insulin attenuates the pulmonary response in animal trauma model. J Trauma 2007; 63: 351-357
95. Chen HI, Yeh DY, Liou HL, et al: Insulin attenuates endotoxin-induced acute lung injury in conscious rats. Crit Care Med 2006; 34:758-764
96. Goldberg RB, Kendall DM, Deeg MA, et al; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28:1547-1554
97. Cuzzocrea S, Pisano B, Dugo L, et al: Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein. Intensive Care Med 2004; 30: 951-956
98. Genovese T, Cuzzocrea S, Di Paola R, et al: Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur Respir J 2005; 25:225-234
99. Liu D, Zeng BX, Zhang SH, et al: Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats. Crit Care Med 2005; 33:2309-2316
100. Cuzzocrea S, Pisano B, Dugo L, et al: Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 2004; 32:457-466
101. Sener G, Sehirli AO, Gedik N, et al: Rosiglitazone, a PPAR-gamma ligand, protects against burn-induced oxidative injury of remote organs. Burns 2007; 33:587-593
102. Zmijewski JW, Lorne E, Zhao X, et al: Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury. Am J Respir Crit Care Med 2008; 178:168-179
103. Ohkubo T, Chapman N, Neal B, et al; Perindopril Protection Against Recurrent Stroke Study Collaborative Group. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 2004; 169: 1041-1045
104. Etminan M, Zhang B, Fitzgerald M, et al: Do angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers decrease the risk of hospitalization secondary to community-acquired pneumonia? A nested case-control study. Pharmacotherapy 2006; 26:479-482
105. Mortensen EM, Pugh MJ, Copeland LA, et al: Impact of statins and angiotensinconverting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008; 31:611-617
106. van de Garde EM, Souverein PC, Hak E, et al: Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes. J Hypertens 2007; 25:235-239
107. Takahashi T, Morimoto S, Okaishi K, et al: Reduction of pneumonia risk by an angiotensin I-converting enzyme inhibitor in elderly Japanese inpatients according to insertion/ deletion polymorphism of the angiotensin I-converting enzyme gene. Am J Hypertens 2005; 18:1353-1359
108. Marshall RP, Webb S, Bellingan GJ, et al: Angiotensin converting enzyme insertion/ deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 166:646-650
109. Adamzik M, Frey U, Sixt S, et al: ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS. Eur Respir J 2007; 29:482-488
110. Jerng JS, Yu CJ, Wang HC, et al: Polymorphism of the angiotensin- converting enzyme gene affects the outcome of acute respiratory distress syndrome. Crit Care Med 2006; 34:1001-1006
111. Boldt J, Papsdorf M, Kumle B, et al: Influence of angiotensin-converting enzyme inhibitor enalaprilat on endothelial-derived substances in the critically ill. Crit Care Med 1998; 26:1663-1670
112. Wiel E, Pu Q, Leclerc J, et al: Effects of the angiotensin-converting enzyme inhibitor perindopril on endothelial injury and hemostasis in rabbit endotoxic shock. Intensive Care Med 2004; 30:1652-1659
113. Lund DD, Brooks RM, Faraci FM, et al: Role of angiotensin II in endothelial dysfunction induced by lipopolysaccharide in mice. Am J Physiol Heart Circ Physiol 2007; 293: H3726-3731
114. Liu H, Zhao J: An experimental study of therapeutic effect of ACEI on chemicalinduced ARDS in rats. Zhonghua Yu Fang Yi Xue Za Zhi 2002; 36:93-96
115. Wö sten-van Asperen RM, Lutter R, Haitsma JJ, et al: ACE mediates ventilatorinduced lung injury in rats via angioten-sin II but not bradykinin. Eur Respir J 2008; 31:363-371
116. Marshall RP, Gohlke P, Chambers RC, et al: Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004; 286: L156-L164
117. The Irish Critical Care Trials Group: Acute lung injury and the acute respiratory distress syndrome in Ireland; a prospective audit of epidemiology and management. Crit Care 2008; 12:R30
118. Yao HW, Mao LG, Zhu JP: Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury. Clin Exp Pharmacol Physiol 2006; 33:793-797
119. Jacobson JR, Barnard JW, Grigoryev DN, et al: Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 2005; 288:L1026-L1032
120. Pirat A, Zeyneloglu P, Aldemir D, et al: Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats. Anesth Analg 2006; 102: 225-232
121. Rivers E, Nguyen B, Havstad S, et al; Early Goal Directed Therapy Collaboration Group: Early-goal directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377
122. Bochicchio GV, Joshi M, Bochicchio KM, et al: Early hyperglycemic control is important in critically injured trauma patients. J Trauma 2007; 63:1353-1358
123. Honiden S, Schultz A, Im SA, et al: Early versus late intravenous insulin administration in critically ill patients. Intensive Care Med 2008; 34:881-887